| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
AstraZeneca |
| Information provided by: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT00536965 |
Purpose
A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <100mg/dl for patients with high risk and <70mg/dl for patients at very high risk) are screened (office-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.
| Condition |
|
Hyperlipidemias Atherosclerosis Coronary Heart Disease Carotid Stenosis Peripheral Vascular Diseases Diabetes Mellitus |
| MedlinePlus related topics: | Diabetes Heart Diseases Peripheral Arterial Disease Vascular Diseases |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | Non-Interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: AstraZeneca Austria Clinical Study, Information | 43 1 71131 277 | paul.grundtner@astrazeneca.com |
| Austria | |||||
| Research Site | Recruiting | ||||
| Vienna, Austria | |||||
| AstraZeneca |
| Study Chair: | Josef Patsch, MD | Chair of the Austrian Atheroslerosis Society |
| Study Chair: | Bernhard Foger, MD | Co-Chair of the Austrian Atheroslerosis Society |
More Information
| Study ID Numbers: | NIS-CAT-CRE-2007/1 |
| First Received: | September 27, 2007 |
| Last Updated: | March 25, 2008 |
| ClinicalTrials.gov Identifier: | NCT00536965 |
| Health Authority: | Not required for this study: |
|
|
|
|
|
